









Markets
/
Stocks
/
nasdaq-mrk
/

Merck & Co Inc

MRK



View Detailed Chart

85.680USD

-0.900-1.04%

Market hours （ET）Quotes delayed by 15 min

214.47BMarket Cap

13.07P/E TTM



Merck & Co Inc

85.680

-0.900-1.04%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.04%

5 Days

-2.20%

1 Month

+9.04%

6 Months

+1.15%

Year to Date

-13.87%

1 Year

-17.40%

View Detailed Chart

TradingKey Stock Score of Merck & Co Inc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Merck & Co Inc's Score

Industry at a Glance

Industry Ranking

34 / 160

Overall Ranking

95 / 4623

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 29 analysts

Buy

Current Rating

99.045

Target Price

+13.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Merck & Co Inc Highlights

StrengthsRisks

Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 64.17B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 46.40%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 46.40%.

Undervalued

The company’s latest PE is 13.31, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.02B shares, decreasing 2.41% quarter-over-quarter.

Held by Irving Kahn

Star Investor Irving Kahn holds 490.46K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.02.

News

Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact

TradingKey - U.S. pharmaceutical giant Merck (MRK.US) has announced a roughly $10 billion deal to acquire U.K.-based biopharma firm Verona Pharma (VRNA.US), marking a major move into the respiratory disease treatment space.

TradingKeyThu, Jul 10

200% Drug Tariff Ultimatum by Trump: Are Patients the Victims of Tariffs?

TradingKey - During a Cabinet meeting at the White House on July 8, Trump announced plans to impose tariffs of up to 200% on imported drugs, requiring pharmaceutical companies to relocate their production chains to the United States and granting them a 1 to 1.5-year adjustment period. If companies..

TradingKeyWed, Jul 9

Merck to Acquire Verona for $10 Billion — A Major Move into Respiratory Care, Shares of VRNA Surge 20%

TradingKey - According to a report by the Financial Times, U.S. pharmaceutical giant Merck (MRK.US) is nearing a deal to acquire Verona Pharma (VRNA.US) for $10 billion, marking Merck’s largest biopharma acquisition since 2023. The acquisition will expand Merck’s presence in the respiratory disease

TradingKeyWed, Jul 9

Trump executive order demands pharma industry price cuts

WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.

ReutersTue, May 13

Merck & Co Inc reports results for the quarter ended December 31 - Earnings Summary

Merck & Co Inc MRK.N reported quarterly adjusted earnings of $1.72 per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 3 cents. The mean expectation of sixteen analysts for the quarter was for earnings of $1.62 per share. Wall ...

ReutersTue, Feb 4

U.S. STOCKS ON THE MOVE-Merck & Co, Sirius XM Holdings, Palantir Technologies

Eikon search string for individual stock moves: The Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv/3dKUyB8U.S. stock index futures were slightly lower on Tuesday as investors stayed away from risky assets after China deployed retaliatory tariffs...

ReutersTue, Feb 4